Barcelona Liver Bioservices (BLB) announced today the presentation of an original communication at the annual meeting of the American Association for the Study of the Liver (AASLD), held as The Liver Meeting Digitial Experience.
Barcelona Liver Bioservices (BLB), CRO specialized in liver diseases, announced today the publication of the manuscript entitled “The pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease” in the peer-reviewed scientific journal Journal of Hepatology.
Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in the field of liver diseases, announced today a non-exclusive collaboration with Surrozen, a biotech company developing tissue-specific antibodies that have the potential to regenerate tissue in situations of serious diseases.
